VWD - Von Willebrand's Disease
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Connect BiopharmaSAN DIEGO, CA
1 programThe Severe Von Willebrand Disease (sVWD) Patient RegistryN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Connect BiopharmaThe Severe Von Willebrand Disease (sVWD) Patient Registry
OctapharmaEqwilate
Clinical Trials (2)
Total enrollment: 438 patients across 2 trials
The Severe Von Willebrand Disease (sVWD) Patient Registry
Start: Dec 2021Est. completion: Dec 2031400 patients
N/ARecruiting
Effectiveness and Tolerability of Eqwilate in Real-life Conditions
Start: Nov 2019Est. completion: Nov 202638 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 438 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.